Skip to main content
. 2022 Nov 11;101(45):e31702. doi: 10.1097/MD.0000000000031702

Table 3.

Multivariate analyses of MSSA/MRSA cases versus controls.

Variable Control vs MSSA Control vs MRSA
Unadjusted model Final adjusted model Unadjusted model Final adjusted model§
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Gender
 Female 0.69 (0.62–0.77) <.01* 0.69 (0.62–0.77) <.01* 1.31 (0.94–1.84) .13
Age
 0–20 Reference Reference Reference
 21–40 0.78 (0.66–0.93) .01* 0.82 (0.72–0.93) .01* 0.95 (0.48–1.87) .89
 41–60 0.71 (0.62–0.83) <.01* 0.74 (0.65–0.85) <.01* 0.71 (0.32–1.55) .40
 >60 0.54 (0.45–0.64) <.01* 0.55 (0.47–0.63) <.01* 1.35 (0.64–2.86) .44
Race (%)
 Mexican American Reference Reference Reference
 Other Hispanic 1.50 (1.25–1.80) <.01* 1.51 (1.27–1.80) <.01* 0.25 (0.04–1.40) .12
 White 1.27 (1.11–1.45) <.01* 1.29 (1.14–1.46) <.01* 1.91 (0.77–4.71) .17
 Black 0.82 (0.74–0.91) <.01* 0.84 (0.77–0.93) <.01* 1.79 (0.82–3.89) .15
 Other Race# 0.92 (0.71–1.19) .53 0.95 (0.73–1.22) .67 1.37 (0.45–4.18) .59
Education (%)
 <High School Diploma Reference
 High School Diploma 1.00 (0.86–1.17) .99
 >High School Diploma 1.09 (0.92–1.28) .32
Number of Household #
 1–3 Reference Reference Reference
 ≥4 1.18 (1.05–1.32) .01 1.19 (1.06–1.33) .01 0.90 (0.44–1.85) .78
Household income (USD)
 <45,000 Reference Reference
 ≥45,000 1.01 (0.91–1.12) .89 0.50 (0.32–0.78) <.01* 0.42 (0.27–0.67) <.01*
Prescription medicine (%)
 No medicine Reference Reference Reference
 Cephalosporins 0.90 (0.58–1.39) .63 0 -
 Macrolides 0.56 (0.31–0.99) .05 0 -
 Penicillins 1.02 (0.73–1.41) .92 1.50 (0.43–5.21) .53
 Fluoroquinolones 0.26 (0.09–0.76) .02* 0.25 (0.09–0.72) .02* 5.28 (1.22–22.82) .03 5.90 (1.37–25.33) .02
 Sulfonamides 0.02 (0.01–0.13) <.01* 0.02 (0.01–0.13) <.01* 0 -
 Tetracyclines 0.19 (0.08–0.46) <.01* 0.19 (0.08–0.46) <.01* 0 -
 Aminoglycosides 0.50 (0.03–9.77) .65 2.65 (0.17–42.17) .50
 Lincomycin derivatives 0.19 (0.03–1.31) .10 0 -
 Antibiotic combination therapy 0.24 (0.12–0.48) <.01* 0.24 (0.12–0.47) <.01* 1.68 (0.25–11.11) .59
 Antibiotics unspecified 0.81 (0.38–1.70) .58 0 -
 Non-antibiotics drugs 1.16 (1.04–1.29) .01* 1.16 (1.03–1.29) .02* 2.28 (1.49–3.49) <.01* 2.51 (1.75–3.60) <.01*
Coughing #
 Yes 0.85 (0.67–1.07) .17 1.27 (0.66–2.44) .49
Long-term care (%)
 Yes 0.61 (0.33–1.12) .12 2.54 (1.21–5.33) .02 2.86 (1.37–5.95) .01
Insurance
 Yes 2.15 (0.99–4.65) .06
Smoking status
 Never-smokers Reference Reference
 Former smokers 0.93 (0.81–1.08) .34 2.07 (1.18–3.66) .02 2.11 (1.26–3.55) .01
 Current smokers 0.75 (0.68–0.84) <.01* 0.73 (0.65–0.81) <.01* 1.04 (0.55–1.98) .90
Diabetes mellitus (%)
 No Reference
 Borderline 1.48 (0.45–4.85) .52
 Yes 1.11 (0.64–1.94) .71

CI = confidence interval, OR = odds ratio.

Unadjusted model, multivariable full models correspond to models including all the variables with P value < 0.20 in univariate analyses.

Final adjusted models for gender, age, race, the total number of people in the household, prescription medicine and smoking status, which correspond to models including all the remaining variables showing significant OR estimates after manual backward-stepwise selections.

§

Final adjusted models for race, household income, fluoroquinolones, long-term care and former smokers, which correspond to models including all the remaining variables showing significant OR estimates after manual backward-stepwise selections.

Non-Hispanic White.

Non-Hispanic Black.

#

Other Race - Including Multi-Racial.

##

The total number of people in the household.

*P < .05.